Current consensus guidelines recommend a 6-week washout period between PD-1 blockade therapy and allo-HSCT, based on the prolonged serum and tissue half-life of anti-PD-1 antibodies to mitigate risks of GVHD (27). This evidence concerns the gene PDCD1 and graft versus host disease.